Late-to-market edoxaban approved in Europe
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's once-daily Factor Xa inhibitor Lixiana (edoxaban) has been approved for use in the EU to prevent stroke and to prevent and treat certain blood clots, without the limitations set by the US regulator.